<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82337">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942148</url>
  </required_header>
  <id_info>
    <org_study_id>031-09-004</org_study_id>
    <secondary_id>JapicCTI-101147</secondary_id>
    <nct_id>NCT01942148</nct_id>
  </id_info>
  <brief_title>A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia</brief_title>
  <official_title>A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pediatric Patients (Aged 13-17 Years) With Schizophrenia (031-09-003 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety and efficacy of aripiprazole
      (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally
      administered over a period of 52 weeks in subjects who complete a short-term treatment study
      of pediatric patients (aged 13-17 years) with schizophrenia (031-09-003 study).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Week1, Week2, Week4, Week8, Week12, Week16, Week24, week32, Week40, Week48, Week52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical golobal impression (CGI)</measure>
    <time_frame>Week1, Week2, Week4, Week8, Week12, Week16, Week24, week32, Week40, Week48, Week52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Global Assessment Scale (CGAS)</measure>
    <time_frame>Week24, Week52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60),
             according to DSM-IV-TR

          -  Male and female patients aged 13-17 years

          -  Patients completing the 031-09-003 study

          -  Patients who, in addition to their legal guardian, provide written informed consent,
             having understood the details of this study

          -  Inpatient or outpatient status

        Exclusion Criteria:

          -  Patients who have a diagnosis of any other disease except schizophrenia, according to
             DSM-IV-TR

          -  Patients who have been compulsorily admitted to hospital

          -  Patients with mental retardation

          -  Patients with thyroid disorder

          -  Patients who fall under a contraindication listed in the ABILIFY package insert

          -  Patients with a serious hepatic, renal, cardiac or hematopoietic disorder

          -  Patients with a history or a complication of organic brain disorder or convulsive
             disorder such as epilepsy

          -  Patients with a history or a complication of diabetes and patients who fall under any
             of the following: fasting blood glucose level ≧ 126 mg/dL, non-fasting blood glucose
             level ≧ 200 mg/dL, HbA1c ≧ 6.5%

          -  Patients with a history or a complication of suicide attempt, suicidal thought or
             self-harm

          -  Patients with a score of ≧2(mild) on PART1 evaluation of CGI-SS

          -  Patients with a history or a complication of malignant syndrome, tardive dyskinesia
             or paralytic ileus

          -  Patients in a state of physical exhaustion accompanied by such conditions as
             dehydration or malnutrition

          -  Patients with a history or a complication of water intoxication

          -  Patients with Parkinson's disease

          -  Pregnant women, parturient women, nursing women, women of childbearing potential who
             wish to become pregnant during this trial.  However, women of childbearing potential
             who are practicing an appropriate method of contraception (refer to 8.6) and have a
             negative pregnancy test result are eligible for inclusion in this study.

          -  Study enrollment is otherwise judged to be inappropriate by the Investigator or
             Subinvestigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, Pediatric patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
